[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650207":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":26,"centralContacts":31,"locations":40,"responsibleParty":92,"collaborators":94,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":103,"sex":108,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":20,"studyType":114,"phases":115,"briefSummary":117,"conditions":118,"keywords":20,"overallStatus":122,"whyStopped":20,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"University Hospital, Grenoble","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Standard therapeutic management with Daridorexant and CPAP in COMISA","Patients with COMISA receiving sequential treatment with Daridorexant and CPAP as part of routine care, with protocolized follow-up and questionnaires (IDSIQ).",[12,13],"Drug: Daridorexant 50 mg","Device: Continuous Positive Air Pressure (CPAP)",[15,21],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Daridorexant 50 mg","Daridorexant initiated for 1 month before CPAP and prescribed as part of routine care.",[9],null,{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":20},"DEVICE","Continuous Positive Air Pressure (CPAP)","PAP therapy initiated after 1 month of Daridorexant, according to standard clinical practice.",[9],[27],{"name":28,"affiliation":29,"role":30},"Jean-Louis PEPIN, Pr","GRENOBLE ALPES UNIVERSITY HOSPITAL","PRINCIPAL_INVESTIGATOR",[32,37],{"name":33,"role":34,"phone":35,"phoneExt":20,"email":36},"Robin TERRAIL","CONTACT","+33476767166","rterrail@chu-grenoble.fr",{"name":38,"role":34,"phone":35,"phoneExt":20,"email":39},"Marie JOYEUX-FAURE, Pr","mjoyeuxfaure@chu-grenoble.fr",[41,56,68,80],{"facility":42,"status":20,"city":43,"state":20,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Hôpital Européen Marseille","Marseille","13003","France","FR",{"type":48,"coordinates":49},"Point",[50,51],5.38107,43.29695,{"lat":51,"lon":50},[54],{"name":55,"role":30,"phone":20,"phoneExt":20,"email":20},"Hervé PEGLIASCO, Dr",{"facility":57,"status":20,"city":58,"state":20,"zip":59,"country":45,"countryCode":46,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Centre Médical Les Jasmins","Metz","57070",{"type":48,"coordinates":61},[62,63],6.17269,49.11911,{"lat":63,"lon":62},[66],{"name":67,"role":30,"phone":20,"phoneExt":20,"email":20},"Khier AMRANI, Dr",{"facility":69,"status":20,"city":70,"state":20,"zip":71,"country":45,"countryCode":46,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Hôpital de la Pitié Salpêtrière - AP-HP","Paris","75013",{"type":48,"coordinates":73},[74,75],2.3488,48.85341,{"lat":75,"lon":74},[78],{"name":79,"role":30,"phone":20,"phoneExt":20,"email":20},"Maxime PATOUT, Dr",{"facility":81,"status":20,"city":82,"state":20,"zip":83,"country":45,"countryCode":46,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Polyclinique Saint-Laurent - Hospitalité Saint-Thomas de Villeneuve","Rennes","35700",{"type":48,"coordinates":85},[86,87],-1.67431,48.11109,{"lat":87,"lon":86},[90],{"name":91,"role":30,"phone":20,"phoneExt":20,"email":20},"Arnaud PRIGENT, Dr",{"type":93,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[95,97,98,100],{"name":81,"class":96},"UNKNOWN",{"name":42,"class":6},{"name":99,"class":96},"Centre Médical les Jasmins \"Poumon et Sommeil\"",{"name":69,"class":96},"100650207","study-on-the-management-of-comisa-100650207",false,"NCT07743931","Study on the Management of COMISA","COMISA-PEC","Inclusion Criteria:\n\n* Adult patient diagnosed with COMISA, defined by an apnea-hypopnea index (AHI) ≥ 15 events\u002Fhour and an Insomnia Severity Index (ISI) score ≥ 15, newly diagnosed and naïve to CPAP therapy and daridorexant treatment (no treatment for \\> 5 years).\n* Prescription of continuous positive airway pressure (CPAP) therapy combined with a prescription of daridorexant.\n* Patient has provided informed consent to participate in the study.\n* Patient is affiliated with a national health insurance system.\n\nExclusion Criteria:\n\n* Severe hepatic impairment (contraindication to daridorexant treatment).\n* Refusal of CPAP therapy and\u002For refusal of daridorexant treatment.\n* Individuals covered under Articles L1121-5 to L1121-8 of the French Public Health Code.\n* Staff members who have a hierarchical relationship with the principal investigator.\n* Any patient who, in the opinion of the investigator, would be unable to comply with study procedures or the study schedule.","ALL","18 Years","75 Years",{"count":112,"type":113},150,"ESTIMATED","INTERVENTIONAL",[116],"NA","COMISA, the combination of obstructive sleep apnea (OSA) and insomnia, is a frequent and burdensome condition. Many patients with OSA experience clinically significant insomnia symptoms, and a substantial proportion of individuals with chronic insomnia also meet criteria for OSA. This comorbidity is associated with more severe symptoms, more complex diagnostic pathways, and reduced adherence to continuous positive airway pressure (CPAP) therapy. This study aims to better understand COMISA and evaluate whether adding daridorexant to CPAP treatment can improve treatment adherence and overall patient outcomes.",[119,120,121],"Obstructive Sleep Apnea (OSA)","Insomnia","COMISA","NOT_YET_RECRUITING","2026-07-31",{"date":125,"type":126},"2026-08-04","ACTUAL",{"date":128,"type":113},"2026-08",{"date":130,"type":113},"2029-02",{"name":5,"class":6},4]